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OBJECTIVE—Klotho is an antiaging hormone present in the
kidney that extends the lifespan, regulates kidney function, and
modulates cellular responses to oxidative stress. We investigated
whether Klotho levels and signaling modulate inﬂammation in
diabetic kidneys.
RESEARCH DESIGN AND METHODS—Renal Klotho expres-
sion was determined by quantitative real-time PCR and immuno-
blot analysis. Primary mouse tubular epithelial cells were treated
with methylglyoxalated albumin, and Klotho expression and
inﬂammatory cytokines were measured. Nuclear factor (NF)-kB
activation was assessed by treating human embryonic kidney
(HEK) 293 and HK-2 cells with tumor necrosis factor (TNF)-a in
the presence or absence of Klotho, followed by immunoblot anal-
ysis to evaluate inhibitor of kB( I kB)a degradation, IkBk i n a s e
(IKK) and p38 activation, RelA nuclear translocation, and phos-
phorylation. A chromatin immunoprecipitation assay was per-
formed to analyze the effects of Klotho signaling on interleukin-8
and monocyte chemoattractant protein-1 promoter recruitment of
RelA and RelA serine (Ser)
536.
RESULTS—Renal Klotho mRNA and protein were signiﬁcantly
decreased in db/db mice, and a similar decline was observed in
the primary cultures of mouse tubule epithelial cells treated with
methylglyoxal-modiﬁed albumin. The exogenous addition of sol-
uble Klotho or overexpression of membranous Klotho in tissue
culture suppressed NF-kB activation and subsequent production
of inﬂammatory cytokines in response to TNF-a stimulation.
Klotho speciﬁcally inhibited RelA Ser
536 phosphorylation as well
as promoter DNA binding of this phosphorylated form of RelA
without affecting IKK-mediated IkBa degradation, total RelA
nuclear translocation, and total RelA DNA binding.
CONCLUSIONS—These ﬁndings suggest that Klotho serves as
an anti-inﬂammatory modulator, negatively regulating the pro-
duction of NF-kB–linked inﬂammatory proteins via a mechanism
that involves phosphorylation of Ser
536 in the transactivation domain
of RelA. Diabetes 60:1907–1916, 2011
I
t has long been recognized that diabetes accelerates
aging, particularly in the subpopulation of diabetic
subjects who are at risk for developing complications
(1). Numerous mechanisms have been proposed, in-
cluding increased production of advanced glycation end
products (AGEs), increased oxidative stress, DNA damage,
and enhanced inﬂammation; it is noteworthy that all of
these mechanisms have been implicated in the pathogenesis
of diabetes complications. Tubular epithelium in the kidneys
from type 2 diabetic patients with demonstrated nephrop-
athy display accelerated senescence, characterized by de-
creased telomere length and an increased expression of
senescence markers (2).
The recent characterization of the Klotho protein as an
antiaging hormone that modulates the expression level of
antioxidant enzymes (3,4), as well as its high expression
level in the kidney (5–7), suggest that Klotho plays a role in
accelerated aging and cellular senescence observed in di-
abetes. Klotho overexpression extends the mouse lifespan
by 20–30% (8). More striking, Klotho-deﬁcient mice exhibit
multiple age-related phenotypes and succumb to early,
premature death (7,9). Klotho is predominantly expressed
in the brain and kidney of normal subjects, and a signiﬁ-
cant decline in Klotho gene and protein expression has
been reported in kidneys of patients with chronic renal
failure (10). Klotho expression is signiﬁcantly suppressed
after the induction of renal ischemia-reperfusion injury,
whereas Klotho overexpression prevented the development
of acute renal failure (11). Also noteworthy, Klotho over-
expression suppressed glomerulonephritis-induced accel-
erated cellular senescence and apoptosis and preserved
renal function (12). Despite these observations, the role of
Klotho in diabetes remains unexplored, even though ac-
celerated aging is associated with this disease.
We investigated potential links between Klotho expres-
sion and diabetes-induced inﬂammation. Our data show
that Klotho suppresses nuclear factor (NF)-kB activation
and the subsequent production of inﬂammatory cytokines
in response to tumor necrosis factor (TNF)-a stimulation
in kidney cells, including primary cultures of mouse tu-
bular epithelium, HK-2, and human embryonic kidney
(HEK) 293 cells. We explored potential mechanism(s) for
this inhibition and identiﬁed a novel and speciﬁc site of
inhibition. Klotho inhibited p38 kinase and speciﬁcally
blocked RelA serine (Ser)
536 phosphorylation and its sub-
sequent recruitment to NF-kB–dependent promoters of
multiple cytokines, without affecting inhibitor of kB
(IkB)a degradation or total RelA nuclear translocation and
DNA binding. These ﬁndings indicate that Klotho serves as
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ORIGINAL ARTICLEan anti-inﬂammatory modulator, regulating the production
of NF-kB–linked inﬂammatory cytokines, chemokines, and
growth factors via a noncanonical NF-kB activation path-
way involving RelA phosphorylation in the transactivation
domain (13–15). Our observations that Klotho can modulate
NF-kB activation and inhibit the production of diabetes-
induced inﬂammatory cytokines suggest that Klotho exerts
a renoprotective effect by increasing the resistance to oxi-
dative stress and inhibiting inﬂammatory cytokine/chemokine
cascades induced by NF-kB activation. Our observations
further suggest that Klotho is a potential therapeutic target
linking oxidative stress to inﬂammation in type 2 diabetes.
RESEARCH DESIGN AND METHODS
Animal and surgical protocols. Male Lepr
db (db/db) and control mice with
the same genetic background (C57BLKS/J) were purchased from The Jackson
Laboratories (Bar Harbor, ME) and housed in the University of Texas Medical
Branch Animal Resource Center in a room with a 12-h light cycle and with free
access to standard diet and water. The animals were cared for in accordance
with the University of Texas Medical Branch Institutional Animal Care and
Use Committee policies and the Public Health Service Guide for the Care and
Use of Laboratory Animals. At 20 weeks of age, the mice were anesthetized
(70/10 mg/kg i.p. ketamine/xylazine), anticoagulated (5 units heparin), then
exsanguinated prior to rapid aortic perfusion with ice-cold PBS to quickly
rinse kidneys free of blood and to deliver a protease inhibitor cocktail (P8340;
Sigma), phosphatase (1 mmol/L orthovanadate and 30 mmol/L sodium ﬂuo-
ride) inhibitors, and dithiothreitol (0.5 mmol/L). Both kidneys were removed,
decapsulated, ﬂash frozen in liquid nitrogen, then stored at 280°C until they
were processed for protein or RNA extraction. A coronal section through
the midline of one kidney at the level of the renal pelvis was ﬁxed in 4%
paraformaldehyde for 24 h, transferred to Hanks’ balanced salt solution, and
stored at 4°C until it was processed for immunohistochemistry.
Isolation and primary culture of renal tubular epithelial cells. Renal
cortical tubular epithelial cells were isolated and cultured using published tech-
niques with modiﬁcations (16). In brief, 12- to 16-week-old C57BL/6 male mice
were used to prepare primary renal proximal tubule cell cultures. Kidneys were
sliced into coronal sections, and the renal cortex was dissected from the medulla,
minced, and then washed three times in ice-cold Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/F12 media containing 0.1% BSA, followed by enzymatic di-
gestion using 1% Worthington collagenase type II and 0.25% soybean trypsin in-
hibitor. Cell suspensions were passed through 200 mesh ﬁlters followed by 325
mesh ﬁlters then resuspended in 45% Percoll and centrifuged at 26,891g for 15
min at 4°C. Proximal tubule cells were sedimented to a layer immediately above
the erythrocyte pellet. Proximal tubule cells were removed, centrifuged, washed
to remove the remaining Percoll, and then resuspended in DMEM/F-12 contain-
ing 50 units/mL penicillin, 50 µg/mL streptomycin, 10 ng/mL epidermal growth
factor, 0.5 mmol/L hydrocortisone, 0.87 mmol/L bovine insulin, 50 mmol/L pros-
taglandin E1, 50 nmol/L sodium selenite, 50 µg/mL human transferrin, and 5 pmol/
L3 , 3 9,5-triiodo-L-thyronine. Cells were plated on Matrigel-coated cover slips, or
plastic cell-culture dishes coated with Matrigel, and maintained in an incubator at
37°C in 5% CO2. Cultures were left undisturbed for 48 h, after which culture
media was replaced every 2 days until cells achieved conﬂuence. For all
experiments, cells were used within ﬁve passages, as described (16).
Cell culture. Human kidney cortex proximal tubular cells, HK-2 (American
Type Culture Collection), were grown and maintained in the recommended
medium, DMEM/Ham’s F12 (50/50) supplemented with 10% FBS, L-glutamine,
insulin, transferrin, sodium selenite, epidermal growth factor (2.5 ng/mL), and
pituitary extract (1.5 mg/mL) in a humidiﬁed atmosphere of 5% CO2. HEK
epithelial cells, (HEK293) were cultured in MEM media with 10% FBS, non-
essential amino acids, sodium pyruvate, and antibiotics in a humidiﬁed at-
mosphere of 5% CO2.
Transient transfection and luciferase activity assay. Transient trans-
fection using lipofectamine PLUS reagent (Invitrogen) was performed in
FIG. 1. Diabetes decreases Klotho protein and message in db/db mice. Kidney cortex from eight control mice and eight db/db mice were lysed in
radioimmunoprecipitation assay buffer for protein or in trizol reagent for RNA extraction. A: Representative Western blots probed with anti-
Klotho antibody (upper panel) and normalized to b-actin as loading controls (lower panel). B: Immunoblotted Klotho and respective b-actin bands
from eight mice were quantiﬁed using a Licor Image Analyzer and normalized to b-actin. Data are means 6 SD of normalized arbitrary scan values.
C: A decline in Klotho transcript, as measured by semiquantitative real-time PCR, is shown. Relative quantiﬁcation of Klotho mRNA was performed
using a MyiQ Single-Color Real-Time PCR Detection System and iQ SYBR Green Supermix, according to the manufacturer’s instructions. Data were
analyzed using the DCT method in reference to GAPDH. n = 8 controls; n =8db/db mice. Signiﬁcantly different from controls by Student t test: *P <
0.05. D: Kidney sections from control and db/db mice were stained with anti-Klotho antibody (upper panel) and counterstained with DAPI for
nuclear staining (lower panel). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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into six-well plates and transfected with 2 µg of construct with a NF-kB–LUC
reporter gene. A total of 48 h after transfection, cells were pretreated with
different concentrations of Klotho (50–200 pmol/L) for 45 min prior to TNF-a
(20 ng/mL) stimulation for 6 h. Cells were lysed, and luciferase activity was
measured using a luminometer. Values were normalized to untreated empty
vector–transfected cells and expressed as fold change over control.
Preparation of methylglyoxal-modiﬁed serum albumin. Human serum
albumin (HSA) minimally modiﬁed by methylglyoxal was prepared by in-
cubation of the protein (100 mmol/L) in sodium phosphate buffer (100 mmol/L
[pH 7.4] and 37°C) with 500 mmol/L methylglyoxal for 24 h, followed by di-
alysis of the modiﬁed protein against ammonium bicarbonate buffer (30 mmol/L
[pH 7.9] and 4°C) for 24 h, and then the dialysis buffer was changed to PBS for
another 24 h. The modiﬁed albumin was sterilized by ﬁltration (0.22 µm) before
aliquoting and storage at 280°C. Unmodiﬁed protein was processed similarly
for control experiments by excluding the 500 mmol/L methylglyoxal. All
reagents used in the preparation of methylglyoxal-modiﬁed human serum
albumin (MG-HSA) were endotoxin free. The extent of modiﬁcation was
determined by amino acid analysis, and ,15% modiﬁc a t i o nw a su s e di nt h i s
study, as reported earlier (17). Negligible levels of endotoxin were detected in
methyglyoxal-modiﬁed human serum albumin (MG-HSA) (0.0019 endotoxin
units [EU]/mL), and control HSA (0.0029 EU/mL) was determined using
a commercially available kit (GenScript, Piscataway, NJ).
Cytokinemeasurements. Multiple cytokines and chemokines were measured
on aliquots of culture media or cell extracts collected after MG-HSA or TNF
treatment using the Bio-Plex system, which is a multiplex bead-based assay
used with the Luminex xMAP technology, according to the manufacturer’s
instructions (Bio-Rad Laboratories, Hercules, CA). Eight-point standard
curves were performed for each cytokine using the same Luminex bead
technology.
Preparation of subcellular extracts. Cells were harvested in PBS, centri-
fuged, and the pellets resuspended sequentially in low-salt, sucrose, and high-
salt solutions to obtain cytosolic and highly puriﬁed nuclear extracts as
previously described (18). Protein concentrations were measured by Coomassie
dye binding (protein reagent; Bio-Rad Laboratories). Efﬁciency of separation of
cytosolic and nuclear proteins was assayed by Western blotting and probing
both samples for cytosolic (b-tubulin and glyceraldehyde-3-phosphate de-
hydrogenase [GAPDH]) and nuclear (lamin B) proteins.
Western immunoblotting. Proteins were fractionated by SDS-PAGE
and transferred to nitrocellulose or polyvinylidene diﬂuoride membranes
(Millipore, Bedford, MA). Membranes were blocked in 5% milk or 5% BSA for
0.5–1 h and then incubated with the indicated primary antibody at 4°C
overnight. Membranes were washed in Tris-buffered saline, 0.1% Tween 20,
and incubated with secondary antibody at 20°C for 1 h. Signals were vi-
sualized by the Odyssey Infrared Imaging System using ﬂuorescent
secondary antibodies or with an enhanced chemiluminescent (ECL) system
onto ﬁlm. b-Actin was used as a loading control.
Quantitative real-time PCR. Total cellular RNA was extracted using Tri
Reagent (Sigma). A total of 2 µg RNA was used for reverse transcription using
the SuperScript III First-Strand Synthesis System from Invitrogen (Carlsbad,
CA). A total of 2 µL cDNA products were ampliﬁed in a 20-µL reaction system
containing 10 µL iQ SYBR Green Supermix (Bio-Rad) and 400 nmol/L primer
mixture. Relevant primers were purchased from SA Bioscience (Frederick,
MD). All reactions were processed in a MyiQ Single Color Real-Time PCR
thermocycler using a two-step–plus–melting curve program. Results were
analyzed by the iQ5 program (Bio-Rad), and the data were analyzed using the
DCT method in reference to GAPDH (19).
Chromatin immunoprecipitation assay. The chromatin immunoprecipita-
tion (ChIP) assay was performed as described (20). In brief, 4–6 3 10
6 cells
were sequentially cross-linked with disuccinimidyl glutarate (Thermo Scientiﬁc,
Rockford, IL) and 1% formaldehyde in PBS, solubilized in 500 mL SDS lysis
buffer (1% SDS; 50 mmol/L Tris [pH 8.0]; and 10 mmol/L EDTA) with a protease
inhibitor cocktail (Sigma-Aldrich), and chromatin sheared by sonication. Equal
amounts of DNA were immunoprecipitated overnight at 4°C with 4 mgo fi n -
dicated antibody. Anti-RelA (sc-372) or IgG (as negative control) were obtained
from Santa Cruz (Santa Cruz, CA). Antiphospho-serine
536 RelA antibodies were
from Cell Signaling (catalog no. 3031; Danvers, MA). Immunoprecipitates were
collected with protein A magnetic beads (Invitrogen). Eluted DNA was de–
cross-linked and used as a template in real-time-PCR. Primers for amplifying
the interleukin (IL)-8 promoter were AGGTTTGCCCTGAGGGGATG (F) and
FIG. 2. MG-HSA induces Klotho depletion and increases cytokine production. Renal primary tubular epithelial cells were treated with MG-HSA
(5 mmol/L) for various times, and expression levels of Klotho (A), RAGE (B), IL-6 (C), and KC (D) were measured by using quantitative RT-PCR.
Data were normalized to GAPDH and expressed as fold change, compared with the untreated cells (0 time interval). Data represent the means 6
SD of three independent experiments and were compared using one-way ANOVA with multiple comparisons, followed by the Tukey post hoc test
for signiﬁcance between time intervals. *P < 0.01 and †P < 0.0001 were signiﬁcantly different than untreated cells.
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(MCP)-1 promoter, the primer sequences were CTGCTTCCCTTTCCTACT (F)
and ATCTTCCATGAGTGATAAGTG (R).
Statistical analysis. Data are reported as means 6 SD. Because all data were
normally distributed on the basis of the Kolmogorov-Smirnov test, both one-
way and two-way ANOVA tests were performed to evaluate overall group
differences. This was followed by the Tukey post hoc test to determine pair-
wise signiﬁcance if the ANOVA test indicated that a signiﬁcant difference was
present in the dataset. In the case of only two group comparisons, a two-
sample Student t test was performed after checking for variance distribution
via the Levene test. In all cases, P , 0.05 was considered signiﬁcant.
RESULTS
Diabetes reduces renal cortical Klotho transcript and
protein levels. As shown in Fig. 1, renal cortical Klotho
protein (by immunoblot) and RNA message (by quantitative
RT-PCR) levels in db/db mice were decreased signiﬁcantly
at 20 weeks of age (after ~12 weeks of hyperglycemia).
Despite heterogeneity in protein expression levels within
each group (Fig. 1A), we observed a 50% decrease in
Klotho protein in the db/db group compared with age- and
sex-matched controls (Fig. 1B). We observed a signiﬁcant
decline (P , 0.01) in Klotho message (mean DCT =1 0 . 4 )
in the diabetic renal cortex compared with the control
renal cortex (mean DCT =4 . 5 )( F i g .1 C), suggesting that
the decline in Klotho protein expression resulted from
suppressed Klotho gene expression. Klotho was pre-
dominantly expressed in tubules but not in the glomeruli
of control mice, with less Klotho immunostaining evident
in diabetic kidneys (Fig. 1D).
AGEs (MG-HSA) induce the loss of Klotho expression
and increase cytokine expression in the primary
cultures of renal tubular epithelium. We previously
have reported noncanonical NF-kB pathway activation in
the renal cortex of db/db mice, with a several-fold in-
crease in NF-kB–inducing kinase (NIK) expression, a key
enzyme regulating activation of this particular NF-kB
pathway (18). Because both Klotho and NIK are pre-
dominantly expressed in renal tubules (6,21), we explored
the possibility that increased NF-kB activation and cytokine
production in the renal tubules of db/db mice are linked to
the decline of Klotho. Renal tubular epithelial cells were
isolated from C57BL/6 mice, and immunoﬂuorescence mi-
croscopy was used to check the purity of the enriched tu-
bular epithelial cell preparation (see Supplementary Fig. 1).
Primary cultures of enriched tubular epithelial cells were
exposed to MG-HSA (5 mmol/L) for 1–24 h followed by RNA
isolation with the trizol reagent. As shown in Fig. 2A and B,
24 h of MG-HSA treatment resulted in a fourfold increase in
the expression of the receptor for AGEs (RAGEs) and a 50%
decline in Klotho levels similar to the decline observed in
vivo. MG-HSA treatment produced a signiﬁcant increase
in proinﬂammatory cytokine mRNA expression for IL-6
(Fig. 2C) and keratinocyte chemoattractant (KC), the mouse
ortholog of IL-8 (Fig. 2D), as well as increased protein levels
for these cytokines in culture media (Supplementary Fig. 2).
The time course of KC production was similar to RAGEs,
whereas IL-6 began to increase within 1 h. These experi-
ments suggest that primary renal tubular cells respond to
MG-HSA by inducing RAGE expression and increased cy-
tokine production and that a diabetic stimulus, such as
MG-HSA, can suppress Klotho expression. Taken together,
these experiments indicate that the diabetic milieu decreases
renal Klotho levels, which may be linked to diabetes-induced
inﬂammation.
Klotho inhibits NF-kB promoter activity. Because the
loss of Klotho in diabetic kidneys could lead to activation
of NF-kB, we investigated whether Klotho negatively
regulates NF-kB pathway activity. HEK293 cells were ﬁrst
transfected with the luciferase plasmid containing the
consensus NF-kB sequence followed by 45 min of pre-
incubation with different concentrations of exogenously
added Klotho prior to TNF-a (20 ng/mL) treatment for 6 h,
as previously described (4). Exogenous addition of Klotho
inhibited NF-kB–dependent promoter activity in a dose-
dependent manner, with an ~70% inhibition observed at
200 pmol/L (Fig. 3A). Klotho was used at this concentra-
tion in subsequent experiments. Klotho also had some
inhibitory effects on basal NF-kB activation in the absence
of TNF-a stimulation (Fig. 3B), suggesting that it might have
a constitutive anti-inﬂammatory role in cells.
Klotho inhibits TNF-a–induced cytokine production.
To further ascertain the inhibitory effect of Klotho on
NF-kB activation, HEK293 cells were preincubated with
200 pmol/L Klotho for 45 min prior to TNF-a (20 ng/mL)
treatment for 1 h; then the cells were lysed in trizol
reagent and the extracted RNA was used for quantitative
RT-PCR. Klotho signiﬁcantly inhibited TNF-a–induced
IL-8, IL-6, regulated upon activation normal T-cell expressed,
and presumably secreted (RANTES), and MCP-1 production
(Fig. 4), although to different extents, which may reﬂect
differences in their kinetics and efﬁcacies of induction by
FIG. 3. Klotho (KL) inhibits TNF-a–induced, NF-kB–dependent pro-
moter activity. A: Dose curve of Klotho inhibition. HEK293 cells
expressing NF-kB–dependent luciferase were preincubated with dif-
ferent concentrations of Klotho for 45 min before stimulating with
TNF-a (20 ng/mL) for 6 h. Values were plotted as fold inhibition com-
pared with TNF-a–treated cells in the absence of Klotho. B: A total of
200 pmol per mL Klotho signiﬁcantly inhibited TNF-a–induced NF-kB
activation. Data represent the means 6 SD of three independent
experiments and were analyzed by one-way ANOVA, followed by
a Tukey post hoc test for signiﬁcance between doses (A) and multiple
treatment groups (B). *P < 0.05 is signiﬁcantly different than controls
(CON); †P < 0.06 and ‡P < 0.01 are signiﬁcantly different than TNF-a–
treated samples.
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Klotho might interfere with TNF-a binding to its receptor,
thereby inhibiting NF-kB activation and cytokine production,
Klotho was transiently overexpressed in HK-2 cells. These
cells were treated with TNF-a (20 ng/mL) for different time
intervals. Figure 5A and B shows that overexpressed Klotho
completely inhibited MCP-1 expression at all time intervals
and signiﬁcantly inhibited IL-8 expression up to 6 h. MCP-1
and IL-8 levels also were measured in culture media (Fig. 5C
and D) and cell lysates (Fig. 5E and F). For these ex-
periments, cells expressing Klotho or vector were ex-
posed to TNF-a for 6 h prior to cytokine measurement
by enzyme-linked immunosorbent assay. Although Klotho
overexpression signiﬁcantly reduced IL-8 in both culture
media and cell lysates, MCP-1 production was signiﬁcantly
reduced only in culture media and did not reach statistical
signiﬁcance in cell lysates (P = 0.08). Supplementary Fig. 3
shows the induced expression level of Klotho in these cells.
Thus, Klotho-mediated inhibition of TNF-a–induced NF-kB
activation is a cellular event and not the physical interfer-
ence of TNF-a binding to its receptor.
Klotho inhibits TNF-a–induced RelA (Ser)
536 phos-
phorylation. To further explore mechanism(s) of Klotho-
mediated inhibition of TNF-a–induced NF-kB activation, we
investigated the impact of Klotho on cytoplasmic and nu-
clear events in NF-kB activation. Figure 6A and Supple-
mentary Fig. 4 show similar TNF-a–induced cytosolic IkBa
degradation in the presence and absence of Klotho, sug-
gesting that Klotho has no effect on IkB kinase (IKK) acti-
vation of the NF-kB canonical pathway. Next, we quantiﬁed
nuclear translocation of total RelA after TNF-a treatment
for 30 min. This experiment demonstrated that increased
RelA nuclear accumulation in response to TNF-a was
unaffected by Klotho treatment (Fig. 6B, top panel and
Supplementary Fig. 5). However, when immunoblotted for
RelA (Ser)
536 phosphorylation, Klotho blocked this phos-
phorylation event in the cytoplasm and to a lesser, but still
signiﬁcant, extent in the nucleus (Fig. 6B, middle panel).
Figures 6C and D provide quantitation of RelA (Ser)
536
immunoblots from three independent experiments. These
results suggest that Klotho speciﬁcally blocked a non-
canonical NF-kB activation pathway mediated by RelA
(Ser)
536 phosphorylation and did not inhibit the IKK-
dependent classical NF-kB activation pathway.
Klotho inhibits p38 kinase. Although several kinases
have been reported to phosphorylate RelA at Ser
536 in re-
sponse to various stimuli (22), IKKb and phosphoinositide
3-kinase (PI3K)/Akt seem to be the predominant kinases
involved. Because Klotho had no effect on TNF-a–induced
IkBa degradation, IKKb may not be a site of action of
Klotho. However, earlier reports have shown that the
exogenous addition of Klotho signiﬁcantly reduced Akt
phosphorylation (4). Moreover, RelA (Ser)
536 phosphory-
lation by Akt has been reported to be mediated via p38
activation (23). Therefore, we investigated if Klotho
inhibits p38 phosphorylation. HEK293 cells were treated
with TNF-a (20 ng/mL for 1 h), and p38 phosphorylation
was examined by immunoblotting. TNF-a treatment in-
creased p38 phosphorylation compared with untreated
cells (Fig. 7A, upper panel), and pretreatment with Klotho
signiﬁcantly reduced the TNF-a–induced phosphorylation.
Immunoblots from three independent experiments were
quantitated and normalized to total p38 and expressed as
fold change versus control cells (Fig. 7A, lower panel). We
also investigated if Klotho inhibited IKKa, another RelA
(Ser)
536 kinase. Although 30 min of TNF-a treatment
FIG. 4. Klotho (KL) inhibits NF-kB–dependent cytokine production. HEK293 cells were treated with TNF-a in the presence of Klotho, and the
effect of Klotho on TNF-a–induced cytokine expression was examined by quantitative RT-PCR using cytokine-speciﬁc primers and normalized to
GAPDH as the internal control. Fold change was calculated by comparing the values to their respective untreated controls (CON). Data represent
the means 6 SD of three independent experiments, and overall signiﬁcance was determined using one-way ANOVA. Signiﬁcance between groups
was analyzed by performing a Turkey post hoc test. *P < 0.05, †P < 0.005, and ‡P < 0.0001 were signiﬁcantly different than control samples,
whereas §P < 0.05 and ||P < 0.0001 were signiﬁcantly different than TNF-a–treated samples.
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exogenously added Klotho failed to inhibit the phosphor-
ylation (Fig. 7B and Supplementary Fig. 6).
Klotho inhibits TNF-a–induced recruitment of phospho-
RelA (Ser)
536 on IL-8 and MCP-1 promoters. We
investigated whether Klotho inhibition of RelA phosphor-
ylation affected its recruitment onto NF-kB–dependent
promoters, leading to inhibition of cytokine production.
HEK293 cells were pretreated with Klotho (200 pmol/L)
f o r4 5m i na n dt h e ns t i m u l a t e dw i t hT N F - a (20 ng/mL) for
30 min. Recruitment of either total RelA or phospho–RelA
(Ser)
536 onto IL-8 and MCP-1 promoters was evaluated by
the ChIP assay. Figure 8A shows a strong induction of
total RelA as well as phospho–RelA (Ser)536 binding on
the MCP-1 promoter after 30 min of TNF-a treatment,
whereas Klotho pretreatment in the absence of TNF-a
had no signiﬁcant effect on their promoter binding. Klotho
treatment signiﬁcantly reduced phospho–RelA (Ser)
536
binding induced by TNF-a (Fig. 8A, lower panel) without
signiﬁcantly affecting total RelA binding to the MCP-1
promoter. Similar results were obtained using the IL-8
promoter (Fig. 8B). Supplementary Fig. 7 shows a repre-
sentative gel from these experiments depicting the simi-
lar changes in the RelA and RelA (Ser)536 recruitment on
both the promoters. These results indicate that Klotho
did not inhibit TNF-a–induced RelA nuclear trans-
location and relevant promoter binding but speciﬁcally
blocked RelA (serine)536 phosphorylation and its bind-
ing to NF-kB–dependent promoters and further sug-
gest that the anti-inﬂammatory effects of Klotho are
mediated via inhibition of this NF-kB noncanonical ac-
tivation pathway.
FIG. 5. Overexpression of Klotho (KL) inhibits MCP-1 and IL-8 expression. HK-2 cells expressing empty vector (EV) or Klotho were treated with
TNF-a (20 ng/mL) for 1–6 h before performing quantitative RT-PCR using IL-8– and MCP-1–speciﬁc primers. Data were normalized to the respective
GAPDH and expressed as fold change compared with untreated cells (A and B). Cells were treated with TNF-a for 6 h before measuring cytokine
levels in culture media (C and D) and cell lysates (E and F) by enzyme-linked immunosorbent assay. Values were normalized to total protein and
expressed as fold change to vector-transfected control cells. Data represent the means 6 SD of three independent experiments and were analyzed by
two-way ANOVA with multiple comparison (time and treatment) and the Tukey post hoc test for signiﬁcance between time intervals and the
treatment groups. *P < 0.05, †P < 0.005, and ‡P < 0.0001 were signiﬁcantly different from control samples. §P < 0.05, ||P < 0.001, and ¶P < 0.0001
were signiﬁcantly different from TNF-a–treated samples.
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The recent characterization of Klotho signaling, an anti-
aging hormone that modulates the expression level of an-
tioxidant enzymes, offers a potentially new focus for
understanding the accelerated senescence and increased
oxidative stress observed in diabetes. Klotho recently has
been shown to have renoprotective effects primarily me-
diated by mitigating mitochondrial oxidative stress and
apoptosis (12). In the current study, we have shown a sig-
niﬁcant decrease of renal Klotho mRNA as well as protein
in db/db mice compared with age- and sex-matched con-
trols, which is consistent with a recent report (24) of
a similar decline of Klotho in kidneys of streptozotocin-
induced diabetic rats. In the latter study, the decline in
Klotho was linked to hyperglycemia because two phar-
macologic approaches to attenuate the severity of hyper-
glycemia (insulin and phloridzin) restored Klotho levels.
We also have reported a novel role for Klotho as a negative
modulator of NF-kB activation via a speciﬁc noncanonical
activation pathway involving RelA (Ser)
536 phosphoryla-
tion. These results suggest that Klotho not only confers
resistance to oxidative stress (4) but may provide pro-
tection against the aberrant activation of NF-kB pathways.
Because Klotho knockout mice exhibit an enhanced aging
phenotype, a diabetes-induced decline in Klotho could be
an unappreciated mechanism linking increased oxidative
stress, inﬂammation, and accelerated aging in the patho-
physiology of diabetic nephropathy.
The concept that diabetes is a chronic inﬂammatory
disease is supported by a rapidly growing array of clinical
and experimental data indicating that inﬂammation, man-
ifested as increases in TNF-a and IL-6, is a common de-
nominator linking obesity, insulin resistance, atherosclerosis,
dyslipidemia, and excessive glucose metabolism in diabetes
(25–28). We recently have reported that chronic NF-kB ac-
t i v a t i o ni nt h er e n a lc o r t e xo fdb/db mice involves a novel
mechanism of NF-kB activation with recruitment of both the
canonical and noncanonical NF-kB pathways (18). In that
study, we have shown that multiple proinﬂammatory cyto-
kines relevant to diabetes, including TNF-a, are increased in
the renal cortex of db/db mice. We have shown here that
Klotho, either expressed transiently as a membranous form
or added exogenously in its soluble form, suppresses TNF-a–
induced NF-kB activation and subsequent production of
proinﬂammatory cytokines such as RANTES, MCP-1, IL-6,
and IL-8. Our rationale for selecting TNF-a as a diabetic
milieu inﬂammatory stimulus was based on clinical and
epidemiological data indicating a role for TNF-a in the
initiation and progression of diabetes, including the fol-
lowing: 1)p r o i n ﬂammatory cytokines such as IL-6, TNF-a,
IL-1b, and plasminogen activator inhibitor-1 are increased
in diabetic patients and are independently correlated with
duration of diabetes (2,29) and 2) acute hyperglycemia
increases circulating levels of IL-6, TNF-a, and IL-18 (30,31).
Although TNF-a expression in insulin-resistant and in di-
abetic subjects has been reported to be several-fold higher
than in control subjects (28,32), these studies remain con-
troversial. TNF-a plays a permissive role in the development
of obesity-induced insulin resistance in mice (33), and
numerous tissue culture experiments have demonstrated
that glucose, AGEs, and a variety of RAGE ligands increase
TNF-a in a variety of cell types (30,34–36). Taken together,
these studies indicate that TNF-a is a product of numerous
diabetic stimuli and suggest that TNF plays an important
upstream role in the activation of NF-kB observed in
diabetes.
There are various regulatory check points for TNF-a–
induced canonical NF-kB pathway activation. Canonical
FIG. 6. Mechanism of Klotho (KL)-mediated NF-kB inhibition. A: Immunoblot showing that pretreatment with Klotho (200 pmol/L) did not inhibit
TNF-a–induced IkBa degradation. Lower panel: b-Actin was used as the loading control. B: Representative Western blot of cytoplasmic extract
(CE) and nuclear extract (NE) of HEK293 cells unstimulated or stimulated with TNF-a (T) with or without Klotho pretreated for 45 min. C and D:
Immunoblots from three independent experiments were quantitated and normalized to respective b-actin and then expressed as fold change vs.
control cells. Results show TNF-a–induced increased RelA Ser
536 phosphorylation and nuclear translocation of both RelA and RelA Ser
536. Klotho
blocks only the serine
536 phosphorylation. Lower panel: b-Actin was used as the loading control. ns, nonspeciﬁc. Data represent the means 6 SD of
three independent experiments, and overall signiﬁcance was determined using one-way ANOVA. Signiﬁcance between groups was analyzed by
performing a Turkey post hoc test. *P < 0.0001 is signiﬁcantly different from control samples, whereas †P < 0.005 is signiﬁcantly different from
TNF-a–treated samples.
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cytoplasm by inhibitors of NF-kB (such as IkB) (37). In
response to stimuli that activate NF-kB via the canonical
pathway, such as TNF-a, there is activation of the IKK
complex; this leads to IkBa phosphorylation at two spe-
ciﬁcN H 2-terminal serine residues of the protein, targeting
it for ubiquitination and subsequent proteosomal degra-
dation (38,39). This process allows cytoplasmically se-
questered RelA p50 dimers to enter the nucleus and bind
to NF-kB promoter sequences to initiate transcription of
speciﬁc genes. Although Klotho inhibited NF-kB activa-
tion, it did not interfere with TNF-a–induced IkBa degra-
dation, total RelA nuclear translocation, or DNA binding,
suggesting that Klotho might use a novel mechanism of
inhibition. Potential possibilities could be inhibition by
posttranslational modiﬁcation of RelA or formation of an
active enhanceosome on NF-kB promoters.
Our ﬁndings differ slightly from the recent observations
of Maekawa et al. (40). Although both studies report a role
for Klotho in modulating NF-kB activity, the latter study
reported that Klotho added exogenously blocked expres-
sion of NF-kB–dependent adhesion molecules by inhibiting
IkBa phosphorylation in response to TNF-a treatment.
Several potential reasons for this discrepancy are appar-
ent, including 1) differences in cell type (human umbilical
vein endothelial cells vs. renal epithelial cells used in our
study), 2) the unique expression of signaling molecules
and distinctive environments of the cultured cells, 3) the
source of Klotho, and 4) the relatively high constitutive
phosphorylation of IkBa in the aortic endothelial cell
control group. It was surprising that these investigators did
not measure total IkBa degradation or inhibition of RelA
nuclear localization by Klotho to buttress their suggestion
of NF-kB canonical pathway inhibition by Klotho.
We have shown that Klotho speciﬁcally inhibited TNF-
a–induced RelA phosphorylation at Ser536 and its sub-
sequent recruitment on IL-8 and MCP-1 promoters, without
affecting total RelA recruitment in response to TNF-a
stimulation. RelA (Ser)
536 phosphorylation has been
shown to occur independently of IkBa degradation (13,14)
and is suggested to be critical for increased NF-kB trans-
activation and subsequent activation of a subset of NF-kB–
dependent genes (14). Although the induction of RelA
nuclear translocation has been regarded as the main event
in NF-kB pathway activation, more recently the phos-
phorylation of RelA at various critical Ser residues in its
transactivation domain has been proposed as a key event
in the activation of NF-kB signaling (22). The literature
suggests that several kinases may phosphorylate the RelA
transactivation domain at Ser
536 in response to TNF-a and
IL-1, including IKKs, PI3K/Akt, TANK-binding kinase-1, and
NIK (15,41). NIK, which is induced several-fold in diabetic
kidneys, has been reported to induce RelA (Ser)
536 phos-
phorylation directly (13), through p38 mitogen-activated
protein kinase (42), or in cooperation with activated Cot (a
serine/threonine kinase) (43,44). In addition, overexpression
of constitutively active Akt increases RelA transactivation
domain phosphorylation in the absence of other stimuli, and
pretreatment of cells with LY294002, a PI3K inhibitor, com-
pletely blocks this phosphorylation event in response to
TNF-a and IL-1 (15,45). Taken together, these results
clearly suggest involvement of PI3K/Akt in TNF-a/IL-1–-
induced RelA (Ser)
536 phosphorylation and subsequent
NF-kB activation. Akt has been proposed to mediate RelA
phosphorylation by activating p38 and requiring both IKKs,
IKKa and IKKb (23). Because we did not observe an in-
hibitory effect of Klotho on TNF-a–induced IkBa degra-
dation, we reasoned that IKKb, which is a potent inducer
of IkBa phosphorylation and its subsequent degradation,
may not be a target of Klotho. Likewise, TANK-binding
kinase-1, which is an IKK-related kinase but not a part of
the IKK complex and not required for IkBa phosphoryla-
tion and degradation, can phosphorylate RelA at Ser536 in
response to TNF-a treatment (46,47). Thus, it is possible
that Klotho may unleash its anti-inﬂammatory effects by
blocking NF-kB activation through inhibiting the PI3K/Akt,
IKKa, or NIK activation normally seen after TNF-a treat-
ment. Our ﬁnding that Klotho blocks p38 phosphorylation is
consistent with earlier observations that Klotho blocks
basal or insulin-induced Akt phosphorylation (4). It will
be important to identify the RelA transactivation domain
kinase, which is sensitive to Klotho to understand how
Klotho suppresses this noncanonical RelA activation
pathway and how its loss contributes to the renal in-
ﬂammation associated with diabetic nephropathy.
In conclusion, we have established that Klotho has an anti-
inﬂammatory function in the kidney in addition to its ability
to engender resistance to oxidative stress. Thus, an adequate
tissue level of Klotho may provide dual protection against
both oxidative stress and inﬂammation, while loss of Klotho
may be a common denominator linking increased oxidative
stress, NF-kB activation, and accelerated aging in diabetes.
FIG. 7. Klotho decreases p38 phosphorylation. A: Western blot showing
that pretreatment of Klotho inhibits TNF-a–induced p38 phosphoryla-
tion (left panel). Immunoblots from three independent experiments
were quantitated and normalized to the respective total p38 and then
expressed as fold change vs. control cells (right panel). Results show
that TNF-a–induced increased p38 phosphorylation is signiﬁcantly re-
duced by the exogenous addition of Klotho. Data represent the means 6
SD of three independent experiments, and overall signiﬁcance was
determined using one-way ANOVA. Signiﬁcance between groups was
analyzed by performing a Turkey post hoc test. *P < 0.001 is signiﬁ-
cantly different from control samples, whereas †P < 0.01 is signiﬁcantly
different from TNF-a–treated samples. C, control; KL, Klotho; T, TNF-a.
B: Klotho-transfected HEK293 cells were treated with or without TNF-a
(20 ng/mL) for 30 min, and whole-cell lysates were immunoblotted with
either phospho-IKKa or total IKKa (loading control). Lower panel:
Expression of transfected Klotho.
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